CVPath Institute appoints Dr. Michael Joner as new CEO

Published on:

GAITHERSBURG, Md., Aug. 27, 2013 -- /PRNewswire-USNewswire/ -- The directors of CVPath Institute, a leading cardiovascular research organization, have appointed Dr. Michael Joner as the Institute's new Chief Executive Officer, announced Dr. Renu Virmani, CVPath's founder, president and medical director. His appointment became effective August 15, 2013. 

"We are thrilled that Michael is joining CVPath in this key leadership role," Dr. Virmani said. "He brings a new dimension to the Institute's cardiovascular research services, given his dual perspective as a clinical scientist who is deeply engaged in patient care, as well as his proven leadership track record. As CEO, he will be responsible for propelling the Institute to the next level of success to ensure that it remains the premier cardiovascular research organization in an ever-changing, highly innovative and competitive field."

Dr. Joner has a distinguished career in cardiovascular medicine, pathology, and technology evaluation.  He completed his medical training at the University of Wuerzburg and spent 2004-2006 as a cardiovascular pathology fellow at the CVPath Institute. After returning to Germany, since 2007 Dr. Joner has been Head of the Preclinical Research at the German Heart Center in Munich, where he also completed his interventional cardiology residency.  Dr. Joner is an accomplished scientist and leader with a track record of working with high-growth medical technology companies.

"I am very excited to return to the CVPath Institute in this challenging and exciting new role," said Dr. Joner, "and I am also delighted that Dr. Virmani will continue as CVPath's Medical Director and board member. I have immense respect for her and her accomplishments, and I greatly enjoy our colleagueship."

About CVPath Institute

CVPath Institute is a leading medical research and education organization dedicated to improving patient health management for those suffering from cardiac and vascular diseases. Established in 2005 as a not-for-profit organization under section 501(c)(3) of the Internal Revenue Code, our mission is to conduct basic and translational "bench to bedside" research. We provide consultation, histology, and diagnostic services to promote discoveries that advance diagnosis and treatment of cardiovascular diseases. For more information, please visit www.cvpath.org.

 

Related Content

Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access
FDA clears AI screening tool for cardiac amyloidosis
IVUS-guided PCI reduces risks in patients with diabetes
SCCT leaders unpack the 2025 Medicare payment increase for coronary CTA
Global shortage of nuclear imaging isotopes may be over
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."